Bionano Stock Financials

BNGO -  USA Stock  

USD 1.94  0.06  3.19%

Understanding current and past Bionano Genomics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Bionano Genomics' financial statements are interrelated, with each one affecting the others. For example, an increase in Bionano Genomics' assets may result in an increase in income on the income statement. Because of this, it is necessary to analyze all of Bionano Genomics' financials over time to get the whole picture.
Bionano Genomics Tangible Asset Value is quite stable at the moment as compared to the past year. The company's current Tangible Asset Value is estimated at 64.28 Million. Working Capital is expected to rise to about 47 M this year, although the value of Average Assets will most likely fall to about 35.9 M.
We suggest to use analysis of Bionano Genomics fundamentals to see if markets are presently mispricing the company. We were able to analyze and collect data for thirty-four available fundamental indicators for Bionano Genomics, which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all Bionano Genomics financials, including its price to sales, book value per share, current asset, as well as the relationship between the cash and equivalents and beta . Please also double-check Bionano Genomics price to earning to validate the company can sustain itself down the road. Use Bionano Genomics to enhance returns of your portfolios. The stock experiences an unexpected upward trend. Watch out for market signals. Check odds of Bionano Genomics to be traded at $2.33 in 90 days.

Bionano Fundamentals 

With this module, you can analyze Bionano financials for your investing period. You should be able to track the changes in Bionano Genomics individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
The fundamental analysis of Bionano Genomics is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Bionano Genomics includes many different criteria found on its balance sheet. For example, investors should never minimize Bionano Genomics' ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Bionano Genomics' cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Bionano Genomics.

Bionano Genomics Cash

Chance Of Financial Distress
Less than 1
Bionano Genomics has less than 1 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Bionano Genomics stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Bionano Genomics' official financial statements usually reflect Bionano Genomics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Bionano Genomics. For example, before you start analyzing numbers published by Bionano accountants, it's critical to develop an understanding of what Bionano Genomics' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Bionano Genomics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bionano Genomics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Bionano Genomics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bionano Genomics. Please utilize our Beneish M Score to check the likelihood of Bionano Genomics' management to manipulate its earnings.

Bionano Genomics Company Summary

Bionano Genomics competes with Berkeley Lights, Burning Rock, Bioventus Inc, Charles River, and Quest Diagnostics. Bionano Genomics, Inc., a genome analysis company, provides tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing. The company was founded in 2006 and is headquartered in San Diego, California. Bionano Genomics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 147 people.
Foreign Associate  Mexico
Healthcare, Diagnostics & Research
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
LocationCalifornia; U.S.A
Business Address9540 Towne Centre
IndustryDiagnostics & Research
Phone858 888 7600
Related EntityBNGO
CurrencyUSD - US Dollar
You should never invest in Bionano Genomics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Bionano Stock, because this is throwing your money away. Analyzing the key information contained in Bionano Genomics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Bionano Genomics Key Financial Ratios

Generally speaking, Bionano Genomics' financial ratios allow both analysts and investors to convert raw data from Bionano Genomics' financial statements into concise, actionable information that can be used to evaluate the performance of Bionano Genomics over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Bionano Genomics reports annually and quarterly.

Bionano Genomics Key Balance Sheet Accounts

201720182019202020212022 (projected)
Total Assets10.15 M24.8 M30.21 M60.45 M69.52 M75.01 M
Current Assets7.14 M23.03 M28.26 M46.79 M53.81 M58.06 M
Assets Non Current3.01 M1.78 M1.95 M13.66 M15.71 M16.95 M
Cash and Equivalents1.02 M16.52 M17.31 M38.45 M44.22 M47.71 M
Total Debt6.73 M9.03 M20.08 M16.33 M18.77 M16.69 M
Deferred Revenue354.63 K271 K357.49 K416 K374.4 K373.12 K
Shareholders Equity(50.23 M)10.14 M3.61 M35.08 M40.34 M43.53 M
Inventory1.69 M1.07 M3.44 M3.32 M3.81 M3.32 M
Total Liabilities17.36 M14.67 M26.59 M25.37 M29.17 M27.01 M
Current Liabilities16.65 M4.52 M26.37 M8.95 M10.29 M13.04 M

Bionano Genomics Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what Bionano Genomics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201720182019202020212022 (projected)
Consolidated Income(23.37 M)(18.5 M)(29.82 M)(41.11 M)(37 M)(39.92 M)
Cost of Revenue6.03 M8.71 M6.77 M5.73 M6.59 M7.04 M
Gross Profit3.47 M3.29 M3.36 M2.77 M2.5 M2.67 M
Interest Expense590.93 K1.38 M2.29 M2.52 M2.9 M2.36 M
Net Income(23.37 M)(18.5 M)(29.82 M)(41.11 M)(37 M)(39.92 M)
Operating Expenses26.69 M23.7 M29.54 M41.33 M47.53 M41.88 M
Operating Income(23.22 M)(20.42 M)(26.17 M)(38.56 M)(34.7 M)(37.44 M)
Revenues9.51 M12 M10.13 M8.5 M9.78 M10.58 M
Income Tax Expense18.55 K15.51 K21.05 K29.19 K33.57 K28.93 K

Bionano Genomics Key Cash Accounts

Cash flow analysis captures how much money flows into and out of Bionano Genomics. It measures of how well Bionano is doing because it can show the actual money that comes into and out of the company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Bionano Genomics brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Bionano had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Bionano Genomics has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
201720182019202020212022 (projected)
Depreciation Amortization and Accretion1.5 M1.32 M1.13 M1.48 M1.7 M1.65 M
Net Cash Flow or Change in Cash and Cash Equivalents(4.23 M)15.5 M788.64 K21.14 M24.31 M26.23 M
Issuance Purchase of Equity Shares14.29 K19.39 M20.56 M66.63 M76.62 M82.67 M
Net Cash Flow from Financing17.61 M35.78 M30.38 M61.9 M71.19 M57.28 M
Net Cash Flow from Investing(1.02 M)(331.72 K)(61.06 K)(2.45 M)(2.2 M)(2.26 M)
Net Cash Flow from Operations(20.82 M)(19.94 M)(29.53 M)(38.31 M)(34.48 M)(37.21 M)
Share Based Compensation382.83 K1.19 M1.35 M1.55 M1.79 M1.47 M

Bionano Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Bionano Genomics's current stock value. Our valuation model uses many indicators to compare Bionano Genomics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bionano Genomics competition to find correlations between indicators driving Bionano Genomics's intrinsic value. More Info.
Bionano Genomics is rated below average in revenue category among related companies. It is number one stock in price to sales category among related companies . The ratio of Revenue to Price to Sales for Bionano Genomics is about  273,568 . Bionano Genomics Revenues is quite stable at the moment as compared to the past year. The company's current value of Revenues is estimated at 10.58 Million. Comparative valuation analysis is a catch-all model that can be used if you cannot value Bionano Genomics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bionano Genomics' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bionano Genomics' earnings, one of the primary drivers of an investment's value.

Bionano Genomics Systematic Risk

Bionano Genomics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Bionano Genomics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourty-eight with a total number of output elements of thirteen. The Beta measures systematic risk based on how returns on Bionano Genomics correlated with the market. If Beta is less than 0 Bionano Genomics generally moves in the opposite direction as compared to the market. If Bionano Genomics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Bionano Genomics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Bionano Genomics is generally in the same direction as the market. If Beta > 1 Bionano Genomics moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

About Bionano Genomics Financials

What exactly are Bionano Genomics Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Bionano Genomics' income statement, its balance sheet, and the statement of cash flows. Potential Bionano Genomics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Bionano Genomics investors may use each financial statement separately, they are all related. The changes in Bionano Genomics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Bionano Genomics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
 2019 2020 2021 2022 (projected)
Current Assets28.26 M46.79 M53.81 M58.06 M
Total Assets30.21 M60.45 M69.52 M75.01 M
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines that you should keep in mind when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase year after year due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt to equity ratio because this number will tell you how much risk it has. If a company such as Bionano Genomics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to try and figure out if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that net revenue of Bionano grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only grown by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

Bionano Genomics Thematic Clasifications

Bionano Genomics is part of Measuring and Control investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Measuring and Control industry as classified by Fama & French. Fama and French focuses on testing asset pricing under different economic assumptions
Measuring and Control Idea
Measuring and ControlView
This theme covers USA Equities from Measuring and Control industry as classified by Fama & French. Fama and French focuses on testing asset pricing under different economic assumptions. Get More Thematic Ideas

Bionano Genomics January 28, 2022 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Bionano Genomics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Bionano Genomics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Bionano Genomics based on widely used predictive technical indicators. In general, we focus on analyzing Bionano Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Bionano Genomics's daily price indicators and compare them against related drivers.
Information Ratio(0.33)
Maximum Drawdown22.24
Value At Risk(7.84)
Potential Upside6.3
Continue to Trending Equities. Note that the Bionano Genomics information on this page should be used as a complementary analysis to other Bionano Genomics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Bionano Stock analysis

When running Bionano Genomics price analysis, check to measure Bionano Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bionano Genomics is operating at the current time. Most of Bionano Genomics' value examination focuses on studying past and present price action to predict the probability of Bionano Genomics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bionano Genomics' price. Additionally, you may evaluate how the addition of Bionano Genomics to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
CEO Directory
Screen CEOs from public companies around the world
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Is Bionano Genomics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine Bionano Genomics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.